Silver Spring, MD – In a groundbreaking regulatory milestone for digital medicine, the U.S. Food and Drug Administration (FDA) has officially qualified the first artificial intelligence (AI) tool designed to assist in the development of treatments for liver disease.
The tool, known as AIM-NASH (recently rebranded as AIM-MASH), was developed by the Boston-based AI pathology leader PathAI. This qualification marks a pivotal shift in how clinical trials for metabolic diseases will be conducted, promising to cut years off drug development timelines and reduce the subjectivity of human diagnosis.
The Historic Milestone
- Date of Qualification: December 9, 2025
- Developer: PathAI
- Target Disease: Metabolically-dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
- Regulatory Status: Qualified under the FDA’s Drug Development Tool (DDT) program.
This is the first time the FDA has qualified an AI-based pathology tool for use in clinical trials for this condition, signalling a major endorsement of AI’s reliability in high-stakes medical research.
What is AIM-MASH?
AIM-MASH is a cloud-based AI system that analyses digital images of liver biopsies. Traditionally, diagnosing MASH requires a pathologist to view a glass slide under a microscope and subjectively score features like inflammation and scarring. This manual process is often slow and prone to variability between different doctors.
How the AI Tool Works:
- Standardised Scoring: The AI scans the biopsy image and generates a precise score for key disease markers:
- Steatosis: Fat accumulation in the liver.
- Inflammation: Swelling and damage to liver cells (hepatocellular ballooning).
- Fibrosis: The extent of scarring.
- Human-in-the-Loop: The FDA qualification specifies that the tool is an adjunct. It does not replace the pathologist but assists them, ensuring that the final diagnosis is consistent and reproducible across different trial sites.
Why This Matters
MASH (Metabolic dysfunction-associated steatohepatitis) is a silent epidemic, often linked to obesity and diabetes, affecting millions globally. Despite its prevalence, drug development has been notoriously difficult, with many late-stage clinical trials failing—partly due to inconsistent methods of measuring whether a drug is actually working.
Impact on Drug Development:
- Speed: Automated analysis can process slides in minutes rather than hours.
- Consistency: Eliminates the “human error” variable where two pathologists might grade the same sample differently.
- Efficiency: Reduces the sample size needed for trials by providing more accurate data, potentially saving millions of dollars in research costs.
Industry Reaction
“This qualification signifies a major advancement in MASH clinical trials,” stated Dr Andy Beck, CEO of PathAI. By securing the FDA’s backing, pharmaceutical companies can now confidently use AIM-MASH in their pivotal Phase 2 and Phase 3 trials without facing regulatory hurdles regarding the tool’s validity.
This move follows a similar qualification by the European Medicines Agency (EMA) earlier in 2025, making AIM-MASH the first AI pathology tool to receive dual backing from both major global regulators.
